"As the head of the R&D department, you actually said it's impossible? Why?"
Okada Murao looked at the subordinates in front of him and was a little angry.
The director of the R&D department smiled bitterly and shook his head: "Mr. Okada, actually this is nothing new. Many pharmaceutical companies have thought about this, but unfortunately they have all failed."
"From Pfizer, Johnson & Johnson, to Takeda Pharmaceuticals, Daiichi Sankyo, etc., they have all tried to find new treatment directions from abandoned prescriptions, but none of them have succeeded."
"Such behavior is highly accidental and cannot be replicated. I believe that even if Sanqing succeeds, it is just bad luck. They will never be so lucky and succeed one after another."
As he explained, he cursed in his heart. The boss must have been under too much pressure recently, and his mind was confused. He had made assumptions and came up with such a bad idea of using discarded prescriptions to develop new drugs.
How could he do something that even the global pharmaceutical giants cannot do?
If you force him to do it, won't it cost his life?
They also say that Sanqing can do it, why can't they do it?
This is not nonsense. Can anti-cancer drugs be developed by just anyone?
If they had this strength, they wouldn't have achieved nothing in ten years of research and development.
Importantly, discovering new therapeutic directions from abandoned pharmacies is not a great innovation.
In fact, when developing new drugs, all pharmaceutical companies and laboratories will conduct a variety of experiments to confirm as many treatment directions as possible.
It is not uncommon for a new drug to suffer setbacks in its original R&D direction, then change its R&D direction and gain new life.
When applying for marketing of innovative drugs, for the sake of safety, they will only apply for a treatment plan for one disease, and then carefully design experiments around this goal. Some will even select patients to obtain satisfactory experimental data, as far as possible. Passed the review by FDA and other departments.
In this case, after the drug is put on the market, some new treatment directions are often discovered during treatment, which can be used for other unrelated diseases.
Even for many drugs that have been on the market for many years, after the patent expires, new treatment directions can be explored and patents for new diseases can be re-registered.
In this regard, the most classic case is the new use of the old drug aspirin.
This best-selling drug has been used clinically for more than 100 years and has always been known for its significant antipyretic and analgesic effects.
But it has a serious side effect, which is that it can cause gastrointestinal bleeding and hemolytic anemia in patients.
In recent years, some teams have begun to study its effectiveness in anticoagulation and inhibiting platelet aggregation. They have used aspirin in patients with strokes and successfully discovered a series of new uses such as treating cerebral thrombosis and preventing myocardial infarction.
It can be said to be an example of an old tree blooming and a successful counterattack with side effects.
Every pharmaceutical company dreams of exploring new research directions for its drugs before their patents expire.
But it’s not something you don’t want to think about, it’s something you can do.
It is not as difficult as developing a brand new drug, and not every pharmaceutical company can make this dream come true.
Luck is very important, but strength is even more important.
Only the top ten pharmaceutical companies in the industry have this strength. Not only can they continuously develop new drugs, but they can also develop new uses for new drugs.
And new directions for research and development also require a large amount of investment again to conduct secondary clinical trials.
Therefore, pharmaceutical companies generally do not act rashly and will continue unless it is as obvious as Viagra.
Otherwise it will just be a waste of a lot of money for nothing.
Eisai's current capital scale cannot afford to waste so much money.
The R&D director is obviously not optimistic about the R&D strength of his department.
It is not easy to discover new treatment directions from successful new drugs, let alone from abandoned prescriptions.
The difficulty of the two is not the same. The former can only be achieved by multinational giants, but the latter is simply a dream. Unless you are the chosen one who is extremely lucky, you will never be able to achieve it.
He didn't want to take on a task that was destined to fail, so he could only persuade his boss to give up this unrealistic idea.
Mr. Okamoto remained silent and his face turned ugly.
Under the reasonable persuasion of his subordinates, he finally regained his sense.
As the R&D director said, it is indeed too difficult to discover new treatment directions from abandoned prescriptions.
He is not arrogant enough to think that he can easily accomplish things that top pharmaceutical companies cannot do.
If he had sufficient funds, he could certainly take the gamble, but he didn't.
But he quickly reacted, frowned, and took it into consideration.
Eisai doesn't have this ability, but Sanqing does.
Although he didn't know how the other party did it, his intuition made him think that the other party could definitely do it.
Otherwise, the other party’s confusing behavior of purchasing discarded prescriptions on a large scale cannot be explained.
If Weicome can't find new opportunities in discarded prescriptions, why does it go on a buying spree?
In this case, why can't he seek cooperation with Sanqing by discarding the prescription?
It is said that the reason why Pfizer was able to reach an anti-cancer drug cooperation with Sanqing was because it provided the largest number of discarded prescriptions, and thus stood out from the many competitors in the bid.
"We don't have much cash left to draw on, probably around $100 million."
Okamoto pondered: "If this money is used to develop new drugs, it will definitely be a drop in the bucket and very difficult. But if it is used to purchase some discarded prescriptions, it will be relatively easy."
He made up his mind: "Hurry up and contact the pharmaceutical companies we have cooperated with and buy discarded prescriptions from them at high prices. I think they will not refuse such a good deal."
The R&D director was stunned: "Boss, you still refuse to give up. Do you still want to compete with Sanqing? This is not a good idea."
"The company's cash flow is already very tight, so we can't waste it all on this. Besides, Sanqing has more money than us now, so we can't compete with them."
Couldn't even the bosses see the fate of the companies that had gone against Sanqing before?
Eisai is no longer what it used to be. Is a run-down pharmaceutical company with an annual revenue of only 2 billion going to fight Sanqing?
The pharmaceutical industry requires not only technology, but also sufficient funds. Those with insufficient funds cannot afford it.
The company needs money but no money, no technology but no technology, and it still wastes money on this kind of place.
If this continues, bankruptcy will happen sooner or later.
Thinking of this, he couldn't help but shudder, and several thoughts flashed through his mind.
Why don't you run away quickly and look for new opportunities?
Before it's too late, switch to a pharmaceutical company and find a new job?
I wonder if Sanqing has any plans to recruit people in Sakura Country. Since we can’t defeat them, why not join them?
His thoughts were racing here, but Mr. Okamoto smiled on the other side.
"Who said I would compete with Sanqing? I plan to use these prescriptions to cooperate with Wei Kang."
"Don't he want to abandon the prescription? Then I will collect more, and then use it to cooperate with him to develop new drug projects. Even if it only accounts for 10%, as long as the research and development is successful, it will be at least ten times the profit, or even It’s a hundred times the profit, it’s a huge profit.”
"My method is very clever. As long as I have enough discarded prescriptions, I don't have to worry about Sanqing not cooperating with us. Hahaha"
Mr. Okamoto's face turned red and he laughed triumphantly.
The R&D director was speechless. He wanted to remind his boss.
If it's so simple, why don't so many pharmaceutical companies do it?
He looked at the boss who was smiling so hard and his face was already a little distorted, and felt a chill in his heart, so he didn't dare to say anything again.
Instead, he lowered his head and responded loudly and respectfully.
"Hey, got it, I'll do my best."
****
"Someone is buying up abandoned prescriptions and raising the price?"
Wei Kang couldn't help but be surprised when he learned the news from An Meina.
Besides him, there are people who want to abandon the prescription?
It's just a matter of buying abandoned prescriptions, he has no control over it. Anyway, there are many pharmaceutical companies in the world, and there are always a lot of companies willing to sell.
But what’s going on with this price increase? Is this to compete with him?
It’s not like no pharmaceutical company has done this before. They want to imitate Sanqing’s operation and recycle waste.
But after they bought it back, they found that they couldn't develop any new treatment directions at all. They were just throwing money into the water without making a sound.
And if you want to stop Sanqing, you just need not to sell the prescriptions you have.
Just like Merck, since anti-cancer drugs were targeted and sales dropped sharply, they have never sold anything from Sanqing.
Purchasing discarded prescriptions from other pharmaceutical companies at such a high price can only harm oneself and benefit others, and give competitors a benefit. It is completely an act that outweighs the gains.
Which pharmaceutical company lost its mind and did such an outrageous thing?
He looked at the details and found that it was a relatively unknown pharmaceutical company.
"Eisai Pharmaceuticals of Sakura Country?"
"It used to be a pharmaceutical giant in the Sakura Country, but now its performance has fallen sharply, and it can only stay in the domestic market."
Anmei introduced it in detail and made an objective evaluation: "They once developed a popular AD drug with very high sales. However, under the impact of Sanqing's special AD drugs, it has completely declined."
"Furthermore, this pharmaceutical company's research and development capabilities are very poor. No innovative drug has been released in the past ten years. It is really not a cause for concern."
"They may be unable to face the blow of reality and want to make a desperate move to learn from your methods and conduct secondary research and development on some abandoned prescriptions to find new treatment directions."
"This is also a trick. Secondary research and development is always easier, and the cost is not that high. It can also avoid some sunk costs. It is a very smart move."
As she spoke, Anmei's speaking speed slowed down, and after two seconds, she suddenly spoke very fast.
"Something surprising happened. I just received a call. It seems to be from the Sakura national pharmaceutical company called Eisai. I want to talk to you. Do you need to be transferred?"
Wei Kang raised his eyebrows, "Good guy, Cao Cao is here right now."
He wanted to see what this company that dared to compete with him and raise prices everywhere wanted to do?
"Take it over."
The phone on the table rang.
After the call was connected, strange and stiff English came out.
"Hello, is this the Sanqing Group? I am the CEO of Sakura Kuni Eisai Pharmaceuticals, Murato Okamoto."
The voice was very flattering, and Wei Kang quickly had a classic image of Sakura Country with a smile on his face, nodding and bowing.
"I'm just, what's the matter with you?" Wei Kang said calmly.
Mr. Okamoto was instantly overjoyed that it was Wei Kang himself and not other subordinates. This was a rare opportunity.
"Mr. Wei, I want to cooperate with you."
"We at Eisai Pharmaceutical currently have a large number of abandoned prescriptions, hundreds of them, all of which have passed the first phase of clinical trials."
"I noticed that you have been acquiring abandoned prescriptions and plan to conduct secondary research and development. Are you interested in the prescriptions I have?"
Mr. Okamoto asked in a very respectful manner.
Wei Kang was a little confused. He cooperated with you to buy discarded prescriptions at a high price. Could it be that he was planning to become a second-rate dealer?
But he is not taken advantage of. If the price is not right, he will not buy it.
"I'm quite interested. Are you planning to sell it to me?" he asked curiously.
"No, no, no, Mr. Wei," Mr. Okamoto said with a smile: "I have spent a lot of effort to acquire these abandoned prescriptions. I have bought all that are currently available on the market. The rest are basically medicines." The company will no longer sell it.”
"In other words, even if you look for acquisitions from other pharmaceutical companies now, you won't be able to buy them anymore. They are all here with me."
Wei Kang felt that something was wrong with the situation, and he said coldly: "What, do you want to show off to me after buying it?"
"Mr. Wei, you misunderstood me," Mr. Okamoto's tone was still very respectful and he continued speaking unhurriedly.
"I said from the beginning that I wanted to cooperate with Sanqing."
"Of course, how to cooperate? I also have my own ideas. How about I use the prescriptions I have to become a shareholder in your new drug project?"
"Based on the cost of drug research and development, after the end of the first phase, it will account for about 30% of the total drug research and development costs."
"My requirements are not high, as long as you give me 10% of the project shares, that's it."
"And if we cooperate, I can also help Sanqing expand the market in Sakura Country. As we all know, the drug market in Sakura Country is very exclusive. Foreign companies will face great resistance if they want to enter. I can help solve these problems."
"What do you think? Is this sincerity enough?"
Okamoto Murao was full of confidence. He felt that he had made a huge concession and there was no reason for Sanqing to refuse.
